Troy Edward Wilson Buys 100,000 Shares of Kura Oncology (NASDAQ:KURA) Stock

Posted by Geri Gentry on Aug 17th, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) CEO Troy Edward Wilson purchased 100,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was purchased at an average cost of $11.12 per share, for a total transaction of $1,112,000.00. Following the completion of the acquisition, the chief executive officer directly owned 379,194 shares of the company’s stock, valued at approximately $4,216,637.28. The trade was a 35.82% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kura Oncology Stock Up 3.9%

KURA stock traded up $0.42 on Monday, hitting $11.28. 2,042,243 shares of the company’s stock were exchanged, compared to its average volume of 1,575,846. The firm has a 50 day moving average price of $10.22 and a two-hundred day moving average price of $9.34. Kura Oncology, Inc. has a 12-month low of $6.95 and a 12-month high of $12.49. The stock has a market cap of $1.00 billion, a P/E ratio of -3.35 and a beta of 0.38. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73.

Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. As a group, equities research analysts expect that Kura Oncology, Inc. will post -3.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KURA has been the subject of a number of recent analyst reports. Jefferies Financial Group set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, May 28th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research note on Thursday, June 4th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $24.00 price target on shares of Kura Oncology in a report on Monday, June 15th. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Oppenheimer set a $24.00 target price on Kura Oncology in a research note on Thursday, May 28th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.62.

Check Out Our Latest Stock Report on KURA

Hedge Funds Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. grew its holdings in Kura Oncology by 69.7% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 568,845 shares of the company’s stock worth $6,240,000 after acquiring an additional 233,633 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock valued at $11,591,000 after acquiring an additional 348,127 shares during the period. UBS Group AG boosted its position in Kura Oncology by 118.3% in the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after purchasing an additional 574,455 shares in the last quarter. Nan Fung Trinity HK Ltd. grew its stake in shares of Kura Oncology by 317.9% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock worth $10,025,000 after purchasing an additional 734,000 shares during the period. Finally, Janney Montgomery Scott LLC grew its stake in shares of Kura Oncology by 285.6% during the 1st quarter. Janney Montgomery Scott LLC now owns 158,850 shares of the company’s stock worth $1,291,000 after purchasing an additional 117,650 shares during the period.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.